Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03967223 |
Recruitment Status :
Active, not recruiting
First Posted : May 30, 2019
Last Update Posted : April 25, 2024
|
Sponsor:
Adaptimmune
Information provided by (Responsible Party):
Adaptimmune
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | August 28, 2024 |
Estimated Study Completion Date : | July 31, 2026 |